Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel

Cardiology (Switzerland)

Volumn 124, Issue 2, 2013, Pages 85-90

  Serebruany, Victor L ^a   Dinicolantonio, James J ^a   Can, Mehmet Mustafa ^a   Goto, Shinya ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiplatelet therapy; Cancer; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; PRASUGREL; TROPONIN; VIMENTIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY OBSTRUCTION; COUGHING; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG FATALITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; LUNG CANCER; LUNG NODULE; MEDICAL HISTORY; PRIORITY JOURNAL; SMOKING; SPINDLE CELL CARCINOMA; THORAX RADIOGRAPHY; UNCLASSIFIED PLEOMORPHIC AND SPINDLE CELL MALIGNANT SOLID NEOPLASM; ARTERY OCCLUSION; CANCER DIAGNOSIS; DRUG ELUTING CARDIOVASCULAR STENT; DRUG IMPLANTATION; DYSPNEA; ELECTROCARDIOGRAPHY; EMERGENCY SURGERY; EMERGENCY WARD; HEMOPTYSIS; HOSPITAL ADMISSION; INSULIN DEPENDENT DIABETES MELLITUS; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; ISCHEMIC WALL MOTION ABNORMALITY; LEFT ANTERIOR-DESCENDENT CORONARY ARTERY OPENING; PROTEIN BLOOD LEVEL; THORAX PAIN; UNCLASSIFIED PLEOMORPHIC AND SPINDLE CELL PULMONARY NEOPLASM; X RAY;

AGED; ASPIRIN; BRAIN NEOPLASMS; CARCINOMA; CLINICAL TRIALS, PHASE III AS TOPIC; COLONIC NEOPLASMS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIOPHENES; TICLOPIDINE; TIME FACTORS;

EID: 84873030784     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000346382     Document Type: Article

References (17)

1. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, the TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
2. Serebruany VL, Shalito I, Kopyleva O: Prasugrel development: claims and achievements. Thromb Haemost 2009; 101: 14-22.
3. Prasugrel Secondary Review. Available for down load at http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-00-FDA.htm (assessed September 26, 2012).
4. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT: Longterm effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.
5. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379: 1591-1601.
6. Blasco-Colmenares E, Perl TM, Guallar E, Baumgartner WA, Conte JV, Alejo D, Pastor-Barriuso R, Sharrett AR, Faraday N: Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009; 169: 788-796.
7. Monroe DM, Hoffman M: The clotting system-a major player in wound healing. Haemophilia 2012; 18(suppl 5):11-16.
8. Bhatt DL, Fox KA, Hacke W, et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
9. Serebruany VL: Prasugrel and cancer risks: potential causes and implications. Am J Med 2009; 122: 407-408.
10. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
11. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V: Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585-1595.
12. Ruiter R, Visser LE, Rodenburg EM, Trifirò G, Ziere G, Stricker BH: Adverse drug reaction-related hospitalizations in persons aged years and over: a population-based study in the Netherlands. Drugs Aging 2012; 29: 225-232.
13. Jensen MD: Androgen effect on body composition and fat metabolism. Mayo Clin Proc 2000; 75:S65-S68.
14. Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S, Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg 2004; 78: 1742-1747.
15. Hagihara M, Higuchi A, Tamura N, Ueda Y, Hirabayashi K, Ikeda Y, Kato S, Sakamoto S, Hotta T, Handa S, Goto S: Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004; 172: 5297-5303.
16. Goto S, Tamura N, Ishida H, Ruggeri ZM: Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5 ? -diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006; 47: 155-162.
17. Roe MT, Armstrong PW, Fox KA, et al: Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-1309.